Therapy Areas: Central Nervous System
22 January 2019 - Promentis Pharmaceuticals Inc, a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced yesterday that it has started a Ph...
22 January 2019 - - US-based Attention Deficit Hyperactivity Disorder treatments provider Ironshore Pharmaceuticals, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., has appointed D...
18 January 2019 - - US-based commercial-stage biopharmaceutical company Omeros Corp. (NASDAQ: OMER) has finalised its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy f...
17 January 2019 - - Italian biopharmaceutical company Newron Pharmaceuticals S.p.A.'s (SIX: NWRN) partner, Zambon S.p.A, together with Valeo Pharma Inc., have announced the approval of Onstryv (s...
15 January 2019 - - US-based RNAi therapeutics company Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) has priced of an underwritten public offering of 5m shares of its common stock at a public offering ...
8 January 2019 - - US-based biopharmaceutical company Sage Therapeutics (NASDAQ: SAGE) has received top-line results from the Phase 3 ROBIN Study, the company said.

This study evaluated t...
Related Headlines